Advanced Cancers: Eradication in All Cases Using 3-bromopyruvate Therapy to Deplete ATP

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2004 Oct 7

PMID 15465013

Citations 150

Authors

Young H Ko

Barbara L Smith

Yuchuan Wang

Martin G Pomper

David A Rini

Michael S Torbenson

Joanne Hullihen

Peter L Pedersen

Affiliations

Soon will be listed here.

Abstract

A common feature of many advanced cancers is their enhanced capacity to metabolize glucose to lactic acid. In a challenging study designed to assess whether such cancers can be debilitated, we seeded hepatocellular carcinoma cells expressing the highly glycolytic phenotype into two different locations of young rats. Advanced cancers (2-3cm) developed and were treated with the alkylating agent 3-bromopyruvate, a lactate/pyruvate analog shown here to selectively deplete ATP and induce cell death. In all 19 treated animals advanced cancers were eradicated without apparent toxicity or recurrence. These findings attest to the feasibility of completely destroying advanced, highly glycolytic cancers.

Citing Articles

Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.

Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J Acta Pharm Sin B. 2024; 14(3):953-1008.

PMID: 38487001 PMC: 10935242. DOI: 10.1016/j.apsb.2023.12.003.

3-bromopyruvate induces morphological alteration and may initiate programmed cell death in Cryptococcus neoformans cells.

Przywara K, Adamski R, Ksiazczyk M, Suchodolski J, Cal M Arch Microbiol. 2024; 206(4):153.

PMID: 38472387 DOI: 10.1007/s00203-024-03894-9.

Succinate metabolism: a promising therapeutic target for inflammation, ischemia/reperfusion injury and cancer.

Zhang W, Lang R Front Cell Dev Biol. 2023; 11:1266973.

PMID: 37808079 PMC: 10556696. DOI: 10.3389/fcell.2023.1266973.

Hnrnpk maintains chondrocytes survival and function during growth plate development via regulating Hif1α-glycolysis axis.

Chen Y, Wu J, Zhang S, Gao W, Liao Z, Zhou T Cell Death Dis. 2022; 13(9):803.

PMID: 36127325 PMC: 9489716. DOI: 10.1038/s41419-022-05239-0.

Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance.

Aria H, Rezaei M, Nazem S, Daraei A, Nikfar G, Mansoori B Front Immunol. 2022; 13:947885.

PMID: 36072596 PMC: 9444135. DOI: 10.3389/fimmu.2022.947885.